{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:49:30Z","timestamp":1767703770166,"version":"3.40.5"},"reference-count":96,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,4,10]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>In the recent years, many novel Disease-Modifying Drugs (DMD) have been introduced to the market in the treatment of multiple sclerosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p>To provide the reader with an up to date, compact review on the pharmacokinetic properties, mechanism of action, and clinical attributes of one of the most recently approved drugs in the therapy of multiple sclerosis, cladribine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Cladribine tablets proved to be a highly efficient treatment choice for Relapsing- Remitting Multiple Sclerosis (RRMS), especially for patients with high disease activity. It is the first DMD for MS with a complex mechanism of action, by inhibiting the adenosine-deaminase enzyme it increases the intracellular levels of deoxyadenosine triphosphate, which with relative selectivity depletes both T- and B-cells lines simultaneously. However long term follow-up safety and effectiveness data are still missing, and clear treatment protocols are lacking beyond the first two treatment years cladribine should prove to be a valuable addition to the therapeutic palette of RRMS, and potentially for Clinically Isolated Syndrome (CIS) as well.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389557519666191015201755","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T16:05:50Z","timestamp":1571846750000},"page":"269-285","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine"],"prefix":"10.2174","volume":"20","author":[{"given":"Tam\u00e1s","family":"Biernacki","sequence":"first","affiliation":[{"name":"Department of Neurology, Szent-Gyorgyi Albert Clinical Center, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1niel","family":"Sandi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Szent-Gyorgyi Albert Clinical Center, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Bencsik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Szent-Gyorgyi Albert Clinical Center, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8037-3672","authenticated-orcid":true,"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Szent-Gyorgyi Albert Clinical Center, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","volume":"83","author":"Browne P.","year":"2014","unstructured":"Browne P.; Chandraratna D.; Angood C.; Tremlett H.; Baker C.; Taylor B.V.; Thompson A.J.; Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 2014,83(11),1022-1024","journal-title":"Neurology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1468-1331.2006.01342.x","volume":"13","author":"Pugliatti M.","year":"2006","unstructured":"Pugliatti M.; Rosati G.; Carton H.; Riise T.; Drulovic J.; V\u00e9csei L.; Milanov I.; The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006,13(7),700-722","journal-title":"Eur J Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2377-13-128","volume":"13","author":"Kingwell E.","year":"2013","unstructured":"Kingwell E.; Marriott J.J.; Jett\u00e9 N.; Pringsheim T.; Makhani N.; Morrow S.A.; Fisk J.D.; Evans C.; B\u00e9land S.G.; Kulaga S.; Dykeman J.; Wolfson C.; Koch M.W.; Marrie R.A.; Incidence and prevalence of multiple sclerosis in Europe: A systematic review. BMC Neurol 2013,13,128","journal-title":"BMC Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/ane.12219","volume":"130","author":"Zsiros V.","year":"2014","unstructured":"Zsiros V.; Fricska-Nagy Z.; F\u00fcvesi J.; Kincses Z.T.; Langane E.; Paulik E.; V\u00e9csei L.; Bencsik K.; Prevalence of multiple sclerosis in Csongr\u00e1d County, Hungary. Acta Neurol Scand 2014,130(5),277-282","journal-title":"Acta Neurol Scand"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.18071\/isz.70.0301","volume":"70","author":"Bencsik K.","year":"2017","unstructured":"Bencsik K.; Sandi D.; Biernacki T.; Kincses Z.; F\u00fcvesi J.; Fricska-Nagy Z.; V\u00e9csei L.; The multiple sclerosis registry of szeged. Ideggyogy Sz 2017,70(9-10),301-306","journal-title":"Ideggyogy Sz"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jns.2016.06.035","volume":"367","author":"Sandi D.","year":"2016","unstructured":"Sandi D.; Zsiros V.; F\u00fcvesi J.; Kincses Z.T.; Fricska-Nagy Z.; Lencs\u00e9s G.; V\u00e9csei L.; Bencsik K.; Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013. J Neurol Sci 2016,367,329-332","journal-title":"J Neurol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"Lublin F.D.","year":"1996","unstructured":"Lublin F.D.; Reingold S.C.; Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996,46(4),907-911","journal-title":"Neurology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"Polman C.H.","year":"2011","unstructured":"Polman C.H.; Reingold S.C.; Banwell B.; Clanet M.; Cohen J.A.; Filippi M.; Fujihara K.; Havrdova E.; Hutchinson M.; Kappos L.; Lublin F.D.; Montalban X.; O\u2019Connor P.; Sandberg-Wollheim M.; Thompson A.J.; Waubant E.; Weinshenker B.; Wolinsky J.S.; Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011,69(2),292-302","journal-title":"Ann Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"Thompson A.J.","year":"2018","unstructured":"Thompson A.J.; Banwell B.L.; Barkhof F.; Carroll W.M.; Coetzee T.; Comi G.; Correale J.; Fazekas F.; Filippi M.; Freedman M.S.; Fujihara K.; Galetta S.L.; Hartung H.P.; Kappos L.; Lublin F.D.; Marrie R.A.; Miller A.E.; Miller D.H.; Montalban X.; Mowry E.M.; Sorensen P.S.; Tintor\u00e9 M.; Traboulsee A.L.; Trojano M.; Uitdehaag B.M.J.; Vukusic S.; Waubant E.; Weinshenker B.G.; Reingold S.C.; Cohen J.A.; Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018,17(2),162-173","journal-title":"Lancet Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"Lublin F.D.","year":"2014","unstructured":"Lublin F.D.; Reingold S.C.; Cohen J.A.; Cutter G.R.; S\u00f8rensen P.S.; Thompson A.J.; Wolinsky J.S.; Balcer L.J.; Banwell B.; Barkhof F.; Bebo B.; Calabresi P.A.; Clanet M.; Comi G.; Fox R.J.; Freedman M.S.; Goodman A.D.; Inglese M.; Kappos L.; Kieseier B.C.; Lincoln J.A.; Lubetzki C.; Miller A.E.; Montalban X.; O\u2019Connor P.W.; Petkau J.; Pozzilli C.; Rudick R.A.; Sormani M.P.; St\u00fcve O.; Waubant E.; Polman C.H.; Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014,83(3),278-286","journal-title":"Neurology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2013.05.010","volume":"333","author":"Lassmann H.","year":"2013","unstructured":"Lassmann H.; Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013,333(1-2),1-4","journal-title":"J Neurol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrn3275","volume":"13","author":"Stys P.K.","year":"2012","unstructured":"Stys P.K.; Zamponi G.W.; van Minnen J.; Geurts J.J.; Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012,13(7),507-514","journal-title":"Nat Rev Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WCO.0000000000000205","volume":"28","author":"Yadav S.K.","year":"2015","unstructured":"Yadav S.K.; Mindur J.E.; Ito K.; Dhib-Jalbut S.; Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol 2015,28(3),206-219","journal-title":"Curr Opin Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1089\/ars.2012.5068","volume":"19","author":"Miljkovi\u0107 D.","year":"2013","unstructured":"Miljkovi\u0107 D.; Spasojevi\u0107 I.; Multiple sclerosis: Molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2013,19(18),2286-2334","journal-title":"Antioxid Redox Signal"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ana.21748","volume":"66","author":"Kebir H.","year":"2009","unstructured":"Kebir H.; Ifergan I.; Alvarez J.I.; Bernard M.; Poirier J.; Arbour N.; Duquette P.; Prat A.; Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009,66(3),390-402","journal-title":"Ann Neurol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/imr.12169","volume":"259","author":"Kleinewietfeld M.","year":"2014","unstructured":"Kleinewietfeld M.; Hafler D.A.; Regulatory T cells in autoimmune neuroinflammation. Immunol Rev 2014,259(1),231-244","journal-title":"Immunol Rev"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707:AID-ANA3>3.0.CO;2-Q","volume":"47","author":"Lucchinetti C.","year":"2000","unstructured":"Lucchinetti C.; Br\u00fcck W.; Parisi J.; Scheithauer B.; Rodriguez M.; Lassmann H.; Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000,47(6),707-717","journal-title":"Ann Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1006\/clim.2000.4944","volume":"98","author":"Constantinescu C.S.","year":"2001","unstructured":"Constantinescu C.S.; Hilliard B.; Ventura E.; Wysocka M.; Showe L.; Lavi E.; Fujioka T.; Scott P.; Trinchieri G.; Rostami A.; Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively. Clin Immunol 2001,98(1),23-30","journal-title":"Clin Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/08916939309043888","volume":"15","author":"Voskuhl R.R.","year":"1993","unstructured":"Voskuhl R.R.; Martin R.; Bergman C.; Dalal M.; Ruddle N.H.; McFarland H.F.; T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 1993,15(2),137-143","journal-title":"Autoimmunity"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"Bettelli E.","year":"2006","unstructured":"Bettelli E.; Carrier Y.; Gao W.; Korn T.; Strom T.B.; Oukka M.; Weiner H.L.; Kuchroo V.K.; Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006,441(7090),235-238","journal-title":"Nature"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cyto.2009.12.003","volume":"50","author":"Edwards L.J.","year":"2010","unstructured":"Edwards L.J.; Robins R.A.; Constantinescu C.S.; Th17\/Th1 phenotype in demyelinating disease. Cytokine 2010,50(1),19-23","journal-title":"Cytokine"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.4049\/jimmunol.1003715","volume":"187","author":"Nyirenda M.H.","year":"2011","unstructured":"Nyirenda M.H.; Sanvito L.; Darlington P.J.; O\u2019Brien K.; Zhang G.X.; Constantinescu C.S.; Bar-Or A.; Gran B.; TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 2011,187(5),2278-2290","journal-title":"J Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12026-014-8529-9","volume":"59","author":"Sinha S.","year":"2014","unstructured":"Sinha S.; Itani F.R.; Karandikar N.J.; Immune regulation of multiple sclerosis by CD8+ T cells. Immunol Res 2014,59(1-3),254-265","journal-title":"Immunol Res"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102048","volume":"18","author":"Lehmann-Horn K.","year":"2017","unstructured":"Lehmann-Horn K.; Kinzel S.; Weber M.S.; Deciphering the role of b cells in multiple sclerosis-towards specific targeting of pathogenic function. Int J Mol Sci 2017,18(10)","journal-title":"Int J Mol Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbadis.2010.06.009","volume":"1812","author":"Weber M.S.","year":"2011","unstructured":"Weber M.S.; Hemmer B.; Cepok S.; The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011,1812(2),239-245","journal-title":"Biochim Biophys Acta"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/135245859800400304","volume":"4","author":"Reiber H.","year":"1998","unstructured":"Reiber H.; Ungefehr S.; Jacobi C.; The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998,4(3),111-117","journal-title":"Mult Scler"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/1352458516664210","volume":"23","author":"Mathias A.","year":"2017","unstructured":"Mathias A.; Perriard G.; Canales M.; Soneson C.; Delorenzi M.; Schluep M.; Du Pasquier R.A.; Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. Mult Scler 2017,23(6),802-809","journal-title":"Mult Scler"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/eji.201040516","volume":"40","author":"Harp C.T.","year":"2010","unstructured":"Harp C.T.; Ireland S.; Davis L.S.; Remington G.; Cassidy B.; Cravens P.D.; Stuve O.; Lovett-Racke A.E.; Eagar T.N.; Greenberg B.M.; Racke M.K.; Cowell L.G.; Karandikar N.J.; Frohman E.M.; Monson N.L.; Memory B cells from a subset of treatment-na\u00efve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-\u03b3 production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 2010,40(10),2942-2956","journal-title":"Eur J Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/314537a0","volume":"314","author":"Lanzavecchia A.","year":"1985","unstructured":"Lanzavecchia A.; Antigen-specific interaction between T and B cells. Nature 1985,314(6011),537-539","journal-title":"Nature"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1084\/jem.20090299","volume":"206","author":"P\u00f6llinger B.","year":"2009","unstructured":"P\u00f6llinger B.; Krishnamoorthy G.; Berer K.; Lassmann H.; B\u00f6sl M.R.; Dunn R.; Domingues H.S.; Holz A.; Kurschus F.C.; Wekerle H.; Spontaneous relapsing-remitting EAE in the SJL\/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009,206(6),1303-1316","journal-title":"J Exp Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1172\/JCI28330","volume":"116","author":"Krishnamoorthy G.","year":"2006","unstructured":"Krishnamoorthy G.; Lassmann H.; Wekerle H.; Holz A.; Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell\/B cell cooperation. J Clin Invest 2006,116(9),2385-2392","journal-title":"J Clin Invest"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1084\/jem.20130699","volume":"210","author":"Molnarfi N.","year":"2013","unstructured":"Molnarfi N.; Schulze-Topphoff U.; Weber M.S.; Patarroyo J.C.; Prod\u2019homme T.; Varrin-Doyer M.; Shetty A.; Linington C.; Slavin A.J.; Hidalgo J.; Jenne D.E.; Wekerle H.; Sobel R.A.; Bernard C.C.; Shlomchik M.J.; Zamvil S.S.; MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013,210(13),2921-2937","journal-title":"J Exp Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"Barr T.A.","year":"2012","unstructured":"Barr T.A.; Shen P.; Brown S.; Lampropoulou V.; Roch T.; Lawrie S.; Fan B.; O\u2019Connor R.A.; Anderton S.M.; Bar-Or A.; Fillatreau S.; Gray D.; B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012,209(5),1001-1010","journal-title":"J Exp Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"34594","DOI":"10.1038\/srep34594","volume":"6","author":"Bjarnad\u00f3ttir K.","year":"2016","unstructured":"Bjarnad\u00f3ttir K.; Benkhoucha M.; Merkler D.; Weber M.S.; Payne N.L.; Bernard C.C.A.; Molnarfi N.; Lalive P.H.; B cell-derived transforming growth factor-\u03b21 expression limits the induction phase of autoimmune neuroinflammation. Sci Rep 2016,6,34594","journal-title":"Sci Rep"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000235","volume":"3","author":"Major E.O.","year":"2016","unstructured":"Major E.O.; Nath A.; A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together. Neurol Neuroimmunol Neuroinflamm 2016,3(3)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.msard.2016.05.010","volume":"9","author":"Giovannoni G.","year":"2016","unstructured":"Giovannoni G.; Kappos L.; Gold R.; Khatri B.O.; Selmaj K.; Umans K.; Greenberg S.J.; Sweetser M.; Elkins J.; McCroskery P.; Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord 2016,9,36-46","journal-title":"Mult Scler Relat Disord"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12883-017-0848-8","volume":"17","author":"Holm\u00f8y T.","year":"2017","unstructured":"Holm\u00f8y T.; von der Lippe H.; Leegaard T.M.; Listeria monocytogenes infection associated with alemtuzumab -- a case for better preventive strategies. BMC Neurol 2017,17(1),65","journal-title":"BMC Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"Giovannoni G.","year":"2010","unstructured":"Giovannoni G.; Comi G.; Cook S.; Rammohan K.; Rieckmann P.; Soelberg S\u00f8rensen P.; Vermersch P.; Chang P.; Hamlett A.; Musch B.; Greenberg S.J.; A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010,362(5),416-426","journal-title":"N Engl J Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","volume":"340","author":"Beutler E.","year":"1992","unstructured":"Beutler E.; Cladribine (2-chlorodeoxyadenosine). Lancet 1992,340(8825),952-956","journal-title":"Lancet"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","volume":"322","author":"Piro L.D.","year":"1990","unstructured":"Piro L.D.; Carrera C.J.; Carson D.A.; Beutler E.; Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990,322(16),1117-1121","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/10428194.2011.570395","volume":"52","author":"Lauria F.","year":"2011","unstructured":"Lauria F.; Cencini E.; Forconi F.; Alternative methods of cladribine administration. Leuk Lymphoma 2011,52(Suppl. 2),34-37","journal-title":"Leuk Lymphoma"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/10428194.2011.570394","volume":"52","author":"Johnston J.B.","year":"2011","unstructured":"Johnston J.B.; Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma 2011,52(Suppl. 2),43-45","journal-title":"Leuk Lymphoma"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3892\/ijo.27.4.1113","volume":"27","author":"Van den Neste E.","year":"2005","unstructured":"Van den Neste E.; Cardoen S.; Offner F.; Bontemps F.; Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: Fludarabine and cladribine. (review). Int J Oncol 2005,27(4),1113-1124","journal-title":"Int J Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-1-4684-5676-9_34","volume":"253B","author":"Wataya Y.","year":"1989","unstructured":"Wataya Y.; Hirota Y.; Hiramoto-Yoshioka A.; Tanaka S.; Otani T.; Minowada J.; Matsuda A.; Ueda T.; The mechanism of 2-chlorodeoxyadenosine-induced cell death. Adv Exp Med Biol 1989,253B,227-234","journal-title":"Adv Exp Med Biol"},{"key":"ref=45","first-page":"6923","volume":"49","author":"Griffig J.","year":"1989","unstructured":"Griffig J.; Koob R.; Blakley R.L.; Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989,49(24 Pt 1),6923-6928","journal-title":"Cancer Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/sj.leu.2402331","volume":"16","author":"Van Den Neste E.","year":"2002","unstructured":"Van Den Neste E.; Cardoen S.; Husson B.; Rosier J.F.; Delacauw A.; Ferrant A.; Van den Berghe G.; Bontemps F.; 2-Chloro-2\u2032-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes. Leukemia 2002,16(1),36-43","journal-title":"Leukemia"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1006\/abbi.1993.1175","volume":"302","author":"Chunduru S.K.","year":"1993","unstructured":"Chunduru S.K.; Appleman J.R.; Blakley R.L.; Activity of human DNA polymerases alpha and beta with 2-chloro-2\u2032-deoxyadenosine 5\u2032-triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys 1993,302(1),19-30","journal-title":"Arch Biochem Biophys"},{"key":"ref=48","first-page":"485","volume":"34","author":"Parker W.B.","year":"1988","unstructured":"Parker W.B.; Bapat A.R.; Shen J.X.; Townsend A.J.; Cheng Y.C.; Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 1988,34(4),485-491","journal-title":"Mol Pharmacol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1016\/S0021-9258(19)39698-X","volume":"265","author":"Hentosh P.","year":"1990","unstructured":"Hentosh P.; Koob R.; Blakley R.L.; Incorporation of 2-halogeno-2\u2032-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem 1990,265(7),4033-4040","journal-title":"J Biol Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-4615-4811-9_29","volume":"457","author":"Richardson D.S.","year":"1999","unstructured":"Richardson D.S.; Allen P.D.; Kelsey S.M.; Newland A.C.; Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells. Adv Exp Med Biol 1999,457,267-279","journal-title":"Adv Exp Med Biol"},{"key":"ref=51","first-page":"4187","volume":"60","author":"Pettitt A.R.","year":"2000","unstructured":"Pettitt A.R.; Sherrington P.D.; Cawley J.C.; Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res 2000,60(15),4187-4193","journal-title":"Cancer Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0006-2952(02)01448-X","volume":"65","author":"Galmarini C.M.","year":"2003","unstructured":"Galmarini C.M.; Voorzanger N.; Falette N.; Jordheim L.; Cros E.; Puisieux A.; Dumontet C.; Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine. Biochem Pharmacol 2003,65(1),121-129","journal-title":"Biochem Pharmacol"},{"key":"ref=53","first-page":"8723","volume":"61","author":"Achanta G.","year":"2001","unstructured":"Achanta G.; Pelicano H.; Feng L.; Plunkett W.; Huang P.; Interaction of p53 and DNA-PK in response to nucleoside analogues: Potential role as a sensor complex for DNA damage. Cancer Res 2001,61(24),8723-8729","journal-title":"Cancer Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0006-2952(03)00410-6","volume":"66","author":"Chow K.U.","year":"2003","unstructured":"Chow K.U.; Nowak D.; Boehrer S.; Ruthardt M.; Knau A.; Hoelzer D.; Mitrou P.S.; Weidmann E.; Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003,66(5),711-724","journal-title":"Biochem Pharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/bjc.1997.577","volume":"76","author":"Borner M.M.","year":"1997","unstructured":"Borner M.M.; Joncourt F.; Hotz M.A.; Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br J Cancer 1997,76(11),1448-1454","journal-title":"Br J Cancer"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1042\/bj3110585","volume":"311","author":"Szondy Z.","year":"1995","unstructured":"Szondy Z.; The 2-chlorodeoxyadenosine-induced cell death signalling pathway in human thymocytes is different from that induced by 2-chloroadenosine. Biochem J 1995,311(Pt 2),585-588","journal-title":"Biochem J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/sj.leu.2403623","volume":"19","author":"Mackus W.J.","year":"2005","unstructured":"Mackus W.J.; Kater A.P.; Grummels A.; Evers L.M.; Hooijbrink B.; Kramer M.H.; Castro J.E.; Kipps T.J.; van Lier R.A.; van Oers M.H.; Eldering E.; Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005,19(3),427-434","journal-title":"Leukemia"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1101\/gad.1126903","volume":"17","author":"Adams J.M.","year":"2003","unstructured":"Adams J.M.; Ways of dying: Multiple pathways to apoptosis. Genes Dev 2003,17(20),2481-2495","journal-title":"Genes Dev"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF01575446","volume":"74","author":"Gartenhaus R.B.","year":"1996","unstructured":"Gartenhaus R.B.; Wang P.; Hoffman M.; Janson D.; Rai K.R.; The induction of p53 and WAF1\/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. J Mol Med (Berl) 1996,74(3),143-147","journal-title":"J Mol Med (Berl)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2001-12-0327","volume":"100","author":"Bellosillo B.","year":"2002","unstructured":"Bellosillo B.; Villamor N.; L\u00f3pez-Guillermo A.; Marc\u00e9 S.; Bosch F.; Campo E.; Montserrat E.; Colomer D.; Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in Beta-cell chronic lymphocytic leukemia. Blood 2002,100(5),1810-1816","journal-title":"Blood"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/sj.onc.1206326","volume":"22","author":"Dewson G.","year":"2003","unstructured":"Dewson G.; Snowden R.T.; Almond J.B.; Dyer M.J.; Cohen G.M.; Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 2003,22(17),2643-2654","journal-title":"Oncogene"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3109\/10428199709050881","volume":"26","author":"Johnston J.B.","year":"1997","unstructured":"Johnston J.B.; Daeninck P.; Verburg L.; Lee K.; Williams G.; Israels L.G.; Mowat M.R.; Begleiter A.; P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997,26(5-6),435-449","journal-title":"Leuk Lymphoma"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/sj.leu.2401649","volume":"14","author":"Nomura Y.","year":"2000","unstructured":"Nomura Y.; Inanami O.; Takahashi K.; Matsuda A.; Kuwabara M.; 2-Chloro-2\u2032-deoxyadenosine induces apoptosis through the Fas\/Fas ligand pathway in human leukemia cell line MOLT-4. Leukemia 2000,14(2),299-306","journal-title":"Leukemia"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1042\/bj3590537","volume":"359","author":"Marzo I.","year":"2001","unstructured":"Marzo I.; P\u00e9rez-Gal\u00e1n P.; Giraldo P.; Rubio-F\u00e9lix D.; Anel A.; Naval J.; Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J 2001,359(Pt 3),537-546","journal-title":"Biochem J"},{"key":"ref=65","first-page":"6408","volume":"60","author":"Sampath D.","year":"2000","unstructured":"Sampath D.; Plunkett W.; The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Res 2000,60(22),6408-6415","journal-title":"Cancer Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nm0596-574","volume":"2","author":"Friesen C.","year":"1996","unstructured":"Friesen C.; Herr I.; Krammer P.H.; Debatin K.M.; Involvement of the CD95 (APO-1\/FAS) receptor\/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996,2(5),574-577","journal-title":"Nat Med"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129182","volume":"10","author":"Korsen M.","year":"2015","unstructured":"Korsen M.; Bragado Alonso S.; Peix L.; Br\u00f6ker B.M.; Dressel A.; Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells. PLoS One 2015,10(6)","journal-title":"PLoS One"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","volume":"32","author":"Liliemark J.","year":"1997","unstructured":"Liliemark J.; The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997,32(2),120-131","journal-title":"Clin Pharmacokinet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40262-017-0516-6","volume":"56","author":"Savic R.M.","year":"2017","unstructured":"Savic R.M.; Novakovic A.M.; Ekblom M.; Munafo A.; Karlsson M.O.; Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet 2017,56(10),1245-1253","journal-title":"Clin Pharmacokinet"},{"year":"2018","unstructured":"Human Medicines European Medicinal Agency2018","journal-title":"Human Medicines","key":"ref=70"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1352458517751792","volume":"24","year":"2018","unstructured":"2017. Mult Scler PACTRIMS2018,24(3),368-423","journal-title":"Mult Scler"},{"year":"2019","unstructured":"Human Medicines European Medicinal Agency2019","journal-title":"Human Medicines","key":"ref=72"},{"year":"2019","unstructured":"Human Medicines European Medicinal Agency2019","journal-title":"Human Medicines","key":"ref=73"},{"year":"2019","unstructured":"Human Medicines European Medicinal Agency2019","journal-title":"Human Medicines","key":"ref=74"},{"year":"2019","unstructured":"Human Medicines European Medicinal Agency2019","journal-title":"Human Medicines","key":"ref=75"},{"year":"2019","unstructured":"Human Medicines European Medicinal Agency2019","journal-title":"Human Medicines","key":"ref=76"},{"year":"2019","unstructured":"Human Medicines European Medicinal Agency2019","journal-title":"Human Medicines","key":"ref=77"},{"year":"2019","unstructured":"Human Medicines European Medicinal Agency2019","journal-title":"Human Medicines","key":"ref=78"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.53.3.448","volume":"53","author":"Fazekas F.","year":"1999","unstructured":"Fazekas F.; Barkhof F.; Filippi M.; Grossman R.I.; Li D.K.; McDonald W.I.; McFarland H.F.; Paty D.W.; Simon J.H.; Wolinsky J.S.; Miller D.H.; The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999,53(3),448-456","journal-title":"Neurology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"Kurtzke J.F.","year":"1983","unstructured":"Kurtzke J.F.; Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983,33(11),1444-1452","journal-title":"Neurology"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","volume":"28","author":"De Stefano N.","year":"2014","unstructured":"De Stefano N.; Airas L.; Grigoriadis N.; Mattle H.P.; O\u2019Riordan J.; Oreja-Guevara C.; Sellebjerg F.; Stankoff B.; Walczak A.; Wiendl H.; Kieseier B.C.; Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014,28(2),147-156","journal-title":"CNS Drugs"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1352458517690269","volume":"24","author":"De Stefano N.","year":"2018","unstructured":"De Stefano N.; Giorgio A.; Battaglini M.; De Leucio A.; Hicking C.; Dangond F.; Giovannoni G.; Sormani M.P.; Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler 2018,24(2),222-226","journal-title":"Mult Scler"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","volume":"4","author":"Giovannoni G.","year":"2015","unstructured":"Giovannoni G.; Turner B.; Gnanapavan S.; Offiah C.; Schmierer K.; Marta M.; Is it time to target No Evident Disease Activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 2015,4(4),329-333","journal-title":"Mult Scler Relat Disord"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","volume":"10","author":"Giovannoni G.","year":"2011","unstructured":"Giovannoni G.; Cook S.; Rammohan K.; Rieckmann P.; S\u00f8rensen P.S.; Vermersch P.; Hamlett A.; Viglietta V.; Greenberg S.; Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis. Lancet Neurol 2011,10(4),329-337","journal-title":"Lancet Neurol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/1352458518771875","volume":"25","author":"Giovannoni G.","year":"2018","unstructured":"Giovannoni G.; Soelberg Sorensen P.; Cook S.; Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler 2018,25(6),819-827","journal-title":"Mult Scler"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ana.23758","volume":"73","author":"Bermel R.A.","year":"2013","unstructured":"Bermel R.A.; You X.; Foulds P.; Hyde R.; Simon J.H.; Fisher E.; Rudick R.A.; Predictors of long-term outcome in multiple sclerosis patients treated with interferon \u03b2. Ann Neurol 2013,73(1),95-103","journal-title":"Ann Neurol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1212\/WNL.0000000000000036","volume":"82","author":"Dobson R.","year":"2014","unstructured":"Dobson R.; Rudick R.A.; Turner B.; Schmierer K.; Giovannoni G.; Assessing treatment response to interferon-\u03b2: Is there a role for MRI? Neurology 2014,82(3),248-254","journal-title":"Neurology"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1177\/1352458509104591","volume":"15","author":"R\u00edo J.","year":"2009","unstructured":"R\u00edo J.; Castill\u00f3 J.; Rovira A.; Tintor\u00e9 M.; Sastre-Garriga J.; Horga A.; Nos C.; Comabella M.; Aymerich X.; Montalb\u00e1n X.; Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009,15(7),848-853","journal-title":"Mult Scler"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1177\/1352458514527863","volume":"20","author":"R\u00edo J.","year":"2014","unstructured":"R\u00edo J.; Rovira A.; Tintor\u00e9 M.; Sastre-Garriga J.; Castill\u00f3 J.; Auger C.; Nos C.; Comabella M.; Tur C.; Vidal \u00c1.; Montalb\u00e1n X.; Evaluating the response to glatiramer acetate in Relapsing-Remitting Multiple Sclerosis (RRMS) patients. Mult Scler 2014,20(12),1602-1608","journal-title":"Mult Scler"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2015.12.043","volume":"361","author":"R\u00edo J.","year":"2016","unstructured":"R\u00edo J.; Ruiz-Pe\u00f1a J.L.; Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci 2016,361,158-167","journal-title":"J Neurol Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/1352458513502399","volume":"20","author":"Prosperini L.","year":"2014","unstructured":"Prosperini L.; Mancinelli C.R.; De Giglio L.; De Angelis F.; Barletta V.; Pozzilli C.; Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler 2014,20(5),566-576","journal-title":"Mult Scler"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"Giovannoni G.","year":"2017","unstructured":"Giovannoni G.; Soelberg Sorensen P.; Cook S.; Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2017,24(12),1594-1604","journal-title":"Mult Scler"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","volume":"14","author":"Giovannoni G.","year":"2017","unstructured":"Giovannoni G.; Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics 2017,14(4),874-887","journal-title":"Neurotherapeutics"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1352458510391344","volume":"17","author":"Cook S.","year":"2011","unstructured":"Cook S.; Vermersch P.; Comi G.; Giovannoni G.; Rammohan K.; Rieckmann P.; S\u00f8rensen P.S.; Hamlett A.; Miret M.; Weiner J.; Viglietta V.; Musch B.; Greenberg S.J.; Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 2011,17(5),578-593","journal-title":"Mult Scler"},{"key":"ref=95","volume":"88","author":"Soelberg-Sorensen P.D.F.","year":"2017","unstructured":"Soelberg-Sorensen P.D.F.; Hicking C.; Giovannoni G.; Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg\/kg in CLARITY and CLARITY Extension (P5.379). Neurology 2017,88(16)","journal-title":"Neurology"},{"key":"ref=96","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000360","volume":"4","author":"Baker D.","year":"2017","unstructured":"Baker D.; Herrod S.S.; Alvarez-Gonzalez C.; Zalewski L.; Albor C.; Schmierer K.; Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm 2017,4(4)","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T22:25:07Z","timestamp":1611613507000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175716\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666191015201755","relation":{},"ISSN":["1389-5575"],"issn-type":[{"type":"print","value":"1389-5575"}],"subject":[],"published":{"date-parts":[[2020,4,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}